Booming Regeneron gets the dirt flying on big R&D expansion

Dr. George Yancopoulos

With blockbuster sales of Eylea spurring some gangbuster projections for Regeneron's future, the booming biotech today launched construction of a 300,000-square-foot R&D facility at its campus in Westchester County, NY.   

BioMed Realty is building the R&D complex for Regeneron ($REGN), which plans to move its scientists into the new center in 2015. And a big group of VIPs--including New York Senator Charles Schumer--were on hand for the silver-spade event.

In addition to its ongoing Phase III program aimed at expanding the label for Eylea, Regeneron also has sarilumab (REGN88) in late-stage studies for rheumatoid arthritis. And analysts have been buzzing over the blockbuster prospects for alirocumab, its PCSK9 antibody for lowering bad cholesterol.

Regeneron CEO Leonard Schleifer and R&D director George Yancopoulos are regularly feted for growing Regeneron into an R&D powerhouse. Sanofi ($SNY) is closely allied to the company, and is relying on Regeneron to provide much of the Big Pharma's biggest innovations.

- here's the press release

Special Reports: 10 top drugs in biopharma's late-stage pipeline - Alirocumab | Top 15 highest paid biopharma R&D chiefs - George Yancopoulos

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.